Covered recipient · General Payments record
DAVID A SARNOW
Allopathic & Osteopathic Physicians Preventive Medicine Aerospace Medicine
General Payments · PY2024
$342.71
- Reported across 16 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $342.71 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $137.26 | 7 |
| ViiV Healthcare Company | $68.31 | 3 |
| PFIZER INC. | $28.29 | 1 |
| Paratek Pharmaceuticals, Inc. | $24.60 | 1 |
| BIOTRONIK NRO, Inc. | $23.17 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $22.63 | 1 |
| Lilly USA, LLC | $21.29 | 1 |
| Tris Pharma Inc | $17.16 | 1 |
By program year
All program years on this page · sorted by year
| Program year | Amount | Records |
|---|---|---|
| PY2024 | $342.71 | 16 |
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| BIOTRONIK NRO, Inc. | $23.17 | 08/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153857760 | CMS |
| Lilly USA, LLC | $21.29 | 06/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136149390 | CMS |
| Novo Nordisk Inc | $18.57 | 05/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096890924 | CMS |
| Novo Nordisk Inc | $22.77 | 06/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097112683 | CMS |
| Novo Nordisk Inc | $17.63 | 06/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097684311 | CMS |
| Novo Nordisk Inc | $19.79 | 07/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097601453 | CMS |
| Novo Nordisk Inc | $20.69 | 07/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096880214 | CMS |
| Novo Nordisk Inc | $18.59 | 08/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097338907 | CMS |
| Novo Nordisk Inc | $19.22 | 08/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096849590 | CMS |
| Paratek Pharmaceuticals, Inc. | $24.60 | 07/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1113917488 | CMS |
| PFIZER INC. | $28.29 | 06/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131452513 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $22.63 | 05/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137668684 | CMS |
| Tris Pharma Inc | $17.16 | 06/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147219976 | CMS |
| ViiV Healthcare Company | $23.69 | 05/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1112791876 | CMS |
| ViiV Healthcare Company | $18.22 | 06/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1112724592 | CMS |
| ViiV Healthcare Company | $26.40 | 07/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1112735905 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2024
- Source files
- Dataset page · Bulk file · PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.